Gilead Sciences (GILD) Should Be Worried: Achillion Pharmaceuticals’ (ACHN) Results For Hep C Drug Due Out Before Year-End

December 22, 2014 3:19 PM

15 0

Gilead faces stiff competition in the hepatitis C market

Gilead Sciences, Inc. (NASDAQ: GILD) should be concerned about Achillion Pharmaceuticals, Inc.’s (NASDAQ:ACHN) experimental hepatitis C drug trial, the results of which are due to be released later this month.

Read more

To category page